Probability of overall survival in all newly diagnosed AML patients (A) and those less than 60 years of age (B) according to Kaplan-Meier calculation in relation to wt1 mRNA (no or weak v intermediate or strong) expression at time of diagnosis. Both de novo AMLs and AMLs with antecedent MDS were included. Patients undergoing allogeneic bone marrow transplantation (BMT) were censored at the time of BMT.